

# Lisa M Butler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8472984/lisa-m-butler-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115  
papers

4,660  
citations

35  
h-index

65  
g-index

144  
ext. papers

5,752  
ext. citations

6.9  
avg, IF

5.49  
L-index

#	Paper	IF	Citations
115	Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover.. <i>Cancer &amp; Metabolism</i> , <b>2022</b> , 10, 1	5.4	1
114	Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
113	Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.. <i>BMC Medicine</i> , <b>2022</b> , 20, 112	11.4	1
112	The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. <i>Gastroenterology</i> , <b>2021</b> ,	13.3	4
111	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , <b>2021</b> , 72, 103625	8.8	5
110	Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 249-270	10.3	5
109	The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis. <i>Gastroenterology</i> , <b>2021</b> , 160, 1224-1239.e30	13.3	26
108	Patient-Derived Prostate Cancer Explants: A Clinically Relevant Model to Assess siRNA-Based Nanomedicines. <i>Advanced Healthcare Materials</i> , <b>2021</b> , 10, e2001594	10.1	5
107	Ex vivo culture of intact human patient derived pancreatic tumour tissue. <i>Scientific Reports</i> , <b>2021</b> , 11, 1944	4.9	12
106	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. <i>Cell Reports</i> , <b>2021</b> , 34, 108585	10.6	10
105	The diversity and breadth of cancer cell fatty acid metabolism. <i>Cancer &amp; Metabolism</i> , <b>2021</b> , 9, 2	5.4	38
104	Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids. <i>Analytical and Bioanalytical Chemistry</i> , <b>2021</b> , 413, 2695-2708	4.4	7
103	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. <i>Nuclear Medicine and Biology</i> , <b>2021</b> , 93, 37-45	2.1	0
102	ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 1704-1718	10.1	16
101	Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 860-870	6.2	5
100	Tumour fatty acid metabolism in the context of therapy resistance and obesity. <i>Nature Reviews Cancer</i> , <b>2021</b> , 21, 753-766	31.3	23
99	A feedback loop between the androgen receptor and 6-phosphogluconate dehydrogenase (6PGD) drives prostate cancer growth. <i>ELife</i> , <b>2021</b> , 10,	8.9	6

98	Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. <i>Cancer Research</i> , <b>2021</b> , 81, 4981-4993	10.1	8
97	Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells. <i>Biointerphases</i> , <b>2020</b> , 15, 031002	1.8	9
96	Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
95	Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. <i>EMBO Reports</i> , <b>2020</b> , 21, e50162	6.5	28
94	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. <i>ELife</i> , <b>2020</b> , 9,	8.9	31
93	eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. <i>Biochemical Journal</i> , <b>2020</b> , 477, 4367-4381	3.8	17
92	Lipogenic effects of androgen signaling in normal and malignant prostate. <i>Asian Journal of Urology</i> , <b>2020</b> , 7, 258-270	2.7	14
91	Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. <i>Histopathology</i> , <b>2020</b> , 76, 976-987	7.3	7
90	Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. <i>Molecular Cancer Research</i> , <b>2020</b> , 18, 1500-1511	6.6	3
89	Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. <i>Advanced Drug Delivery Reviews</i> , <b>2020</b> , 159, 245-293	18.5	96
88	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). <i>BMJ Open</i> , <b>2020</b> , 10, e033667	3	5
87	Sex differences in corneal neovascularization in response to superficial corneal cautery in the rat. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221566	3.7	1
86	Maximizing RNA Loading for Gene Silencing Using Porous Silicon Nanoparticles. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2019</b> , 11, 22993-23005	9.5	15
85	Cancer-associated fibroblasts-heroes or villains?. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 293-302	8.7	89
84	Evaluation of Small Molecule Drug Uptake in Patient-Derived Prostate Cancer Explants by Mass Spectrometry. <i>Scientific Reports</i> , <b>2019</b> , 9, 15008	4.9	10
83	Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e16534-e16534	2.2	2
82	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 631-640	11.5	110
81	Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 949-962	6.6	41

80	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1151-1159	7.5	11
79	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2328-2341	12.9	32
78	Precision nanomedicines for prostate cancer. <i>Nanomedicine</i> , <b>2018</b> , 13, 803-807	5.6	6
77	Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. <i>BJU International</i> , <b>2018</b> , 121 Suppl 3, 9-21	5.6	36
76	Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. <i>Molecular and Cellular Proteomics</i> , <b>2018</b> , 17, 1470-1486	7.6	19
75	Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 713-726	8.7	20
74	Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. <i>Scientific Reports</i> , <b>2018</b> , 8, 2090	4.9	15
73	Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 308-317	4.2	28
72	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2018</b> , 8,	5.4	17
71	A patient-derived explant (PDE) model of hormone-dependent cancer. <i>Molecular Oncology</i> , <b>2018</b> , 12, 1608-1622	7.9	54
70	Osteoblast derived-neurotrophin-3 induces cartilage removal proteases and osteoclast-mediated function at injured growth plate in rats. <i>Bone</i> , <b>2018</b> , 116, 232-247	4.7	7
69	Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. <i>European Urology Oncology</i> , <b>2018</b> , 1, 325-337	6.7	23
68	Culture and Lentiviral Transduction of Benign Prostatic Hyperplasia (BPH) Samples. <i>Bio-protocol</i> , <b>2018</b> , 8,	0.9	2
67	An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 54-54	2.2	
66	The inverse relationship between prostate specific antigen (PSA) and obesity. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 933-941	5.7	13
65	A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. <i>Oncogene</i> , <b>2017</b> , 36, 24-34	9.2	73
64	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , <b>2017</b> , 77, 1021-1034	10.1	74
63	The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2689-2700	6.1	22

62	A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response. <i>Prostate</i> , <b>2016</b> , 76, 1546-1559	4.2	18
61	IBI mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. <i>BMC Cancer</i> , <b>2016</b> , 16, 141	4.8	6
60	High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 44492-44504	3.3	11
59	Small Glutamine-Rich Tetratricopeptide Repeat-Containing Protein Alpha (SGTA) Ablation Limits Offspring Viability and Growth in Mice. <i>Scientific Reports</i> , <b>2016</b> , 6, 28950	4.9	7
58	Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, R219-27	5.7	54
57	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, 805-18	5.7	18
56	Maximizing the Therapeutic Potential of HSP90 Inhibitors. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 1445-51	6.6	123
55	Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. <i>Oncotarget</i> , <b>2015</b> , 6, 37919-29	3.3	18
54	Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers. <i>Prostate</i> , <b>2014</b> , 74, 547-60	4.2	9
53	Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and (4)-tibolone. <i>Molecular and Cellular Endocrinology</i> , <b>2014</b> , 382, 899-908	4.4	2
52	Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, L17-21	5.7	29
51	Altered endosome biogenesis in prostate cancer has biomarker potential. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 1851-62	6.6	19
50	Molecular pathology and prostate cancer therapeutics: from biology to bedside. <i>Journal of Pathology</i> , <b>2014</b> , 232, 178-84	9.4	26
49	Bringing androgens up a NOTCH in breast cancer. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, T183-202	5.7	21
48	Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. <i>Menopause</i> , <b>2014</b> , 21, 79-88	2.5	13
47	Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. <i>Prostate</i> , <b>2013</b> , 73, 182-93	4.2	14
46	SGTA: a new player in the molecular co-chaperone game. <i>Hormones and Cancer</i> , <b>2013</b> , 4, 343-57	5	22
45	Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. <i>BMC Biochemistry</i> , <b>2013</b> , 14, 10	4.8	11

44	Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2812-23	7.5	13
43	Circulating microRNAs predict biochemical recurrence in prostate cancer patients. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 641-50	8.7	98
42	Hsp90: still a viable target in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2013</b> , 1835, 211-8	11.2	23
41	Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , <b>2013</b> , 10, 483-5	7.5	96
40	Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. <i>Nature Communications</i> , <b>2013</b> , 4, 1923	17.4	106
39	Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease. <i>Methods in Molecular Biology</i> , <b>2013</b> , 1024, 235-46	1.4	3
38	Targeting cell cycle and hormone receptor pathways in cancer. <i>Oncogene</i> , <b>2013</b> , 32, 5481-91	9.2	82
37	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. <i>Oncotarget</i> , <b>2013</b> , 4, 691-704	3.3	43
36	Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 357, 60-70	4.4	35
35	Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli. <i>American Journal of Pathology</i> , <b>2012</b> , 181, 2225-38	5.8	18
34	Dual roles of PARP-1 promote cancer growth and progression. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1134-49	24.4	260
33	An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 599-613	5.7	35
32	Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. <i>Cell Cycle</i> , <b>2012</b> , 11, 2756-61	4.7	171
31	Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3562-70	12.9	85
30	Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 652-61	7.5	139
29	A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 662-72	7.5	28
28	Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. <i>Journal of Molecular Endocrinology</i> , <b>2012</b> , 49, 57-68	4.5	19
27	Circulating microRNAs: macro-utility as markers of prostate cancer?. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, R99-R113	5.7	34

26	Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. <i>Molecular and Cellular Endocrinology</i> , <b>2011</b> , 342, 20-31	4.4	12
25	GSTP1 DNA methylation and expression status is indicative of 5-aza-2'deoxyctidine efficacy in human prostate cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e25634	3.7	41
24	Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. <i>Medical Journal of Indonesia</i> , <b>2010</b> , 5	0.4	2
23	Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 2611-22 <sup>4</sup>		119
22	Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 6131-40	10.1	277
21	Finding the place of histone deacetylase inhibitors in prostate cancer therapy. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 619-30	3.8	4
20	The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2009</b> , 1795, 104-9	11.2	11
19	Insights from AR Gene Mutations <b>2009</b> , 207-240		1
18	Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2008</b> , 110, 236-43	5.1	57
17	The contribution of different androgen receptor domains to receptor dimerization and signaling. <i>Molecular Endocrinology</i> , <b>2008</b> , 22, 2373-82		103
16	Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. <i>FASEB Journal</i> , <b>2007</b> , 21, 2285-93	0.9	71
15	Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. <i>Cancer Research</i> , <b>2007</b> , 67, 10087-96	10.1	80
14	Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 51-60	6.1	88
13	The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 944-54	7.5	62
12	Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. <i>Molecular Endocrinology</i> , <b>2006</b> , 20, 1009-24		16
11	GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor. <i>Biological Chemistry</i> , <b>2005</b> , 386, 69-74	4.5	24
10	Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. <i>Cancer Research</i> , <b>2005</b> , 65, 8487-96	10.1	55
9	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , <b>2004</b> , 11, 459-76	5.7	192

8	The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 11700-5	11.5	448
7	Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 577-81		52
6	Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 131-5	8.7	26
5	Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. <i>Australian and New Zealand Journal of Surgery</i> , <b>1999</b> , 69, 88-94		36
4	The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma. <i>Cancer Letters</i> , <b>1999</b> , 143, 29-35	9.9	17
3	Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 1454-9	8.7	38
2	Androgens and the androgen receptor (AR)378-391		
1	Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition		2